AstraZeneca reports results from the ARCTIC trial in third-line non-small cell lung cancer
AstraZeneca and MedImmune, its global biologics research and development arm, announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or...
BERG Announces the Dosing of First UK Patient in Phase II Combination Trial of BPM 31510 and Gemcitabine for Patients with Pancreatic Cancer
ERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, announced the dosing of the first patient in the...
Prothena Announces Global Neuroscience R&D Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases
Prothena Corporation plc , a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan...
Roche’s TECENTRIQ plus chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous...
Roche announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab)...
Tasigna drug to treat children with rare form of leukemia receives FDA approval: Novartis
Novartis announced that the US FDA expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of...
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
GSK announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus (SLE)....
Praluent extensively reduces risk of cardiovascular events in high-risk patients, and was associated with lower death rate
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing Praluent® (alirocumab) significantly reduced the risk of major adverse...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...